Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.64 |
| ▸ | CCND1 | P24385 | 7/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.56 |
| ▸ | CDK9 | P50750 | 5/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.56 |
| ▸ | CDK11A | Q9UQ88 | 5/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.55 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743097 | 0.92 | CDK4 (0.68) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5741249 | 0.90 | CDK4 (0.71) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5743018 | 0.88 | CDK4 (0.83) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5743992 | 0.86 | CCNA2 (0.68) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5744164 | 0.81 | CDK4 (0.74) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5743331 | 0.81 | CDK4 (0.59) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5742043 | 0.80 | CDK4 (0.66) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5742172 | 0.80 | CDK4 (0.82) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5743411 | 0.80 | CDK4 (0.87) | CDK4CCND1CCNT1CDK9CDK6 | |
| SCHEMBL5744023 | 0.79 | TUBB8B (0.61) | CDK4CCND1CCNT1CDK9CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | claimed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | claimed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | claimed |
| US-7105670-B2 | Intermediates useful in the preparation of diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-7094896-B2 | Diaminothiazoles having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1358169-B1 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | HOFFMANN LA ROCHE (CH) | 2006-01-11 | — | — | EP | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 34/4885CCNT1 31/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 34/4885CCNT1 31/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 39/4885CCNT1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.